

Global AAV Vector Gene Therapy Market Growth 2023-2029

<https://marketpublishers.com/r/GA91B73FBE3DEN.html>

Date: November 2023

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: GA91B73FBE3DEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global AAV Vector Gene Therapy market size was valued at US\$ million in 2022. With growing demand in downstream market, the AAV Vector Gene Therapy is forecast to a readjusted size of US\$ million by 2029 with a CAGR of % during review period.

The research report highlights the growth potential of the global AAV Vector Gene Therapy market. AAV Vector Gene Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of AAV Vector Gene Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the AAV Vector Gene Therapy market.

AAV (Adeno-Associated Virus) vector gene therapy is a gene therapy method that uses adeno-associated virus as a vector to deliver, express or repair specific genes in patients. AAV is a non-pathogenic, non-oncogenic virus that is widely used in gene therapy research and clinical trials.

Key Features:

The report on AAV Vector Gene Therapy market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size

and growth of the AAV Vector Gene Therapy market. It may include historical data, market segmentation by Type (e.g., AAV1, AAV2), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the AAV Vector Gene Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the AAV Vector Gene Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the AAV Vector Gene Therapy industry. This include advancements in AAV Vector Gene Therapy technology, AAV Vector Gene Therapy new entrants, AAV Vector Gene Therapy new investment, and other innovations that are shaping the future of AAV Vector Gene Therapy.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the AAV Vector Gene Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for AAV Vector Gene Therapy product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the AAV Vector Gene Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting AAV Vector Gene Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the AAV Vector Gene Therapy market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the AAV Vector Gene Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report concludes with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the AAV Vector Gene Therapy market.

Market Segmentation:

AAV Vector Gene Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

AAV1

AAV2

AAV8

Other

Segmentation by application

Duchenne Dystrophy

Hemophilia

Retinal Diseases

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

uniQure

Roche

Novartis

BioMarin Pharmaceutical

Ferring Pharmaceuticals A/S

CSL Behring LLC

PTC Therapeutics, Inc.

Pfizer Inc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global AAV Vector Gene Therapy market?

What factors are driving AAV Vector Gene Therapy market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do AAV Vector Gene Therapy market opportunities vary by end market size?

How does AAV Vector Gene Therapy break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global AAV Vector Gene Therapy Annual Sales 2018-2029

- 2.1.2 World Current & Future Analysis for AAV Vector Gene Therapy by Geographic Region, 2018, 2022 & 2029

- 2.1.3 World Current & Future Analysis for AAV Vector Gene Therapy by Country/Region, 2018, 2022 & 2029

2.2 AAV Vector Gene Therapy Segment by Type

- 2.2.1 AAV1

- 2.2.2 AAV2

- 2.2.3 AAV8

- 2.2.4 Other

2.3 AAV Vector Gene Therapy Sales by Type

- 2.3.1 Global AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)

- 2.3.2 Global AAV Vector Gene Therapy Revenue and Market Share by Type (2018-2023)

- 2.3.3 Global AAV Vector Gene Therapy Sale Price by Type (2018-2023)

2.4 AAV Vector Gene Therapy Segment by Application

- 2.4.1 Duchenne Dystrophy

- 2.4.2 Hemophilia

- 2.4.3 Retinal Diseases

- 2.4.4 Other

2.5 AAV Vector Gene Therapy Sales by Application

- 2.5.1 Global AAV Vector Gene Therapy Sale Market Share by Application (2018-2023)

- 2.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Application

(2018-2023)

2.5.3 Global AAV Vector Gene Therapy Sale Price by Application (2018-2023)

3 GLOBAL AAV VECTOR GENE THERAPY BY COMPANY

3.1 Global AAV Vector Gene Therapy Breakdown Data by Company

3.1.1 Global AAV Vector Gene Therapy Annual Sales by Company (2018-2023)

3.1.2 Global AAV Vector Gene Therapy Sales Market Share by Company (2018-2023)

3.2 Global AAV Vector Gene Therapy Annual Revenue by Company (2018-2023)

3.2.1 Global AAV Vector Gene Therapy Revenue by Company (2018-2023)

3.2.2 Global AAV Vector Gene Therapy Revenue Market Share by Company
(2018-2023)

3.3 Global AAV Vector Gene Therapy Sale Price by Company

3.4 Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers AAV Vector Gene Therapy Product Location Distribution

3.4.2 Players AAV Vector Gene Therapy Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION

4.1 World Historic AAV Vector Gene Therapy Market Size by Geographic Region
(2018-2023)

4.1.1 Global AAV Vector Gene Therapy Annual Sales by Geographic Region
(2018-2023)

4.1.2 Global AAV Vector Gene Therapy Annual Revenue by Geographic Region
(2018-2023)

4.2 World Historic AAV Vector Gene Therapy Market Size by Country/Region
(2018-2023)

4.2.1 Global AAV Vector Gene Therapy Annual Sales by Country/Region (2018-2023)

4.2.2 Global AAV Vector Gene Therapy Annual Revenue by Country/Region
(2018-2023)

4.3 Americas AAV Vector Gene Therapy Sales Growth

4.4 APAC AAV Vector Gene Therapy Sales Growth

4.5 Europe AAV Vector Gene Therapy Sales Growth

4.6 Middle East & Africa AAV Vector Gene Therapy Sales Growth

5 AMERICAS

5.1 Americas AAV Vector Gene Therapy Sales by Country

5.1.1 Americas AAV Vector Gene Therapy Sales by Country (2018-2023)

5.1.2 Americas AAV Vector Gene Therapy Revenue by Country (2018-2023)

5.2 Americas AAV Vector Gene Therapy Sales by Type

5.3 Americas AAV Vector Gene Therapy Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC AAV Vector Gene Therapy Sales by Region

6.1.1 APAC AAV Vector Gene Therapy Sales by Region (2018-2023)

6.1.2 APAC AAV Vector Gene Therapy Revenue by Region (2018-2023)

6.2 APAC AAV Vector Gene Therapy Sales by Type

6.3 APAC AAV Vector Gene Therapy Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe AAV Vector Gene Therapy by Country

7.1.1 Europe AAV Vector Gene Therapy Sales by Country (2018-2023)

7.1.2 Europe AAV Vector Gene Therapy Revenue by Country (2018-2023)

7.2 Europe AAV Vector Gene Therapy Sales by Type

7.3 Europe AAV Vector Gene Therapy Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa AAV Vector Gene Therapy by Country

8.1.1 Middle East & Africa AAV Vector Gene Therapy Sales by Country (2018-2023)

8.1.2 Middle East & Africa AAV Vector Gene Therapy Revenue by Country
(2018-2023)

8.2 Middle East & Africa AAV Vector Gene Therapy Sales by Type

8.3 Middle East & Africa AAV Vector Gene Therapy Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy

10.3 Manufacturing Process Analysis of AAV Vector Gene Therapy

10.4 Industry Chain Structure of AAV Vector Gene Therapy

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 AAV Vector Gene Therapy Distributors

11.3 AAV Vector Gene Therapy Customer

12 WORLD FORECAST REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION

- 12.1 Global AAV Vector Gene Therapy Market Size Forecast by Region
 - 12.1.1 Global AAV Vector Gene Therapy Forecast by Region (2024-2029)
 - 12.1.2 Global AAV Vector Gene Therapy Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global AAV Vector Gene Therapy Forecast by Type
- 12.7 Global AAV Vector Gene Therapy Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 uniQure
 - 13.1.1 uniQure Company Information
 - 13.1.2 uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
 - 13.1.3 uniQure AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 uniQure Main Business Overview
 - 13.1.5 uniQure Latest Developments
- 13.2 Roche
 - 13.2.1 Roche Company Information
 - 13.2.2 Roche AAV Vector Gene Therapy Product Portfolios and Specifications
 - 13.2.3 Roche AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Roche Main Business Overview
 - 13.2.5 Roche Latest Developments
- 13.3 Novartis
 - 13.3.1 Novartis Company Information
 - 13.3.2 Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
 - 13.3.3 Novartis AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Novartis Main Business Overview
 - 13.3.5 Novartis Latest Developments
- 13.4 BioMarin Pharmaceutical
 - 13.4.1 BioMarin Pharmaceutical Company Information

13.4.2 BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications

13.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 BioMarin Pharmaceutical Main Business Overview

13.4.5 BioMarin Pharmaceutical Latest Developments

13.5 Ferring Pharmaceuticals A/S

13.5.1 Ferring Pharmaceuticals A/S Company Information

13.5.2 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications

13.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Ferring Pharmaceuticals A/S Main Business Overview

13.5.5 Ferring Pharmaceuticals A/S Latest Developments

13.6 CSL Behring LLC

13.6.1 CSL Behring LLC Company Information

13.6.2 CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications

13.6.3 CSL Behring LLC AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 CSL Behring LLC Main Business Overview

13.6.5 CSL Behring LLC Latest Developments

13.7 PTC Therapeutics, Inc.

13.7.1 PTC Therapeutics, Inc. Company Information

13.7.2 PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications

13.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 PTC Therapeutics, Inc. Main Business Overview

13.7.5 PTC Therapeutics, Inc. Latest Developments

13.8 Pfizer Inc.

13.8.1 Pfizer Inc. Company Information

13.8.2 Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications

13.8.3 Pfizer Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Pfizer Inc. Main Business Overview

13.8.5 Pfizer Inc. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. AAV Vector Gene Therapy Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. AAV Vector Gene Therapy Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of AAV1
- Table 4. Major Players of AAV2
- Table 5. Major Players of AAV8
- Table 6. Major Players of Other
- Table 7. Global AAV Vector Gene Therapy Sales by Type (2018-2023) & (K Units)
- Table 8. Global AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)
- Table 9. Global AAV Vector Gene Therapy Revenue by Type (2018-2023) & (\$ million)
- Table 10. Global AAV Vector Gene Therapy Revenue Market Share by Type (2018-2023)
- Table 11. Global AAV Vector Gene Therapy Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 12. Global AAV Vector Gene Therapy Sales by Application (2018-2023) & (K Units)
- Table 13. Global AAV Vector Gene Therapy Sales Market Share by Application (2018-2023)
- Table 14. Global AAV Vector Gene Therapy Revenue by Application (2018-2023)
- Table 15. Global AAV Vector Gene Therapy Revenue Market Share by Application (2018-2023)
- Table 16. Global AAV Vector Gene Therapy Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 17. Global AAV Vector Gene Therapy Sales by Company (2018-2023) & (K Units)
- Table 18. Global AAV Vector Gene Therapy Sales Market Share by Company (2018-2023)
- Table 19. Global AAV Vector Gene Therapy Revenue by Company (2018-2023) (\$ Millions)
- Table 20. Global AAV Vector Gene Therapy Revenue Market Share by Company (2018-2023)
- Table 21. Global AAV Vector Gene Therapy Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 22. Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution and Sales Area

- Table 23. Players AAV Vector Gene Therapy Products Offered
- Table 24. AAV Vector Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 25. New Products and Potential Entrants
- Table 26. Mergers & Acquisitions, Expansion
- Table 27. Global AAV Vector Gene Therapy Sales by Geographic Region (2018-2023) & (K Units)
- Table 28. Global AAV Vector Gene Therapy Sales Market Share Geographic Region (2018-2023)
- Table 29. Global AAV Vector Gene Therapy Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 30. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region (2018-2023)
- Table 31. Global AAV Vector Gene Therapy Sales by Country/Region (2018-2023) & (K Units)
- Table 32. Global AAV Vector Gene Therapy Sales Market Share by Country/Region (2018-2023)
- Table 33. Global AAV Vector Gene Therapy Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 34. Global AAV Vector Gene Therapy Revenue Market Share by Country/Region (2018-2023)
- Table 35. Americas AAV Vector Gene Therapy Sales by Country (2018-2023) & (K Units)
- Table 36. Americas AAV Vector Gene Therapy Sales Market Share by Country (2018-2023)
- Table 37. Americas AAV Vector Gene Therapy Revenue by Country (2018-2023) & (\$ Millions)
- Table 38. Americas AAV Vector Gene Therapy Revenue Market Share by Country (2018-2023)
- Table 39. Americas AAV Vector Gene Therapy Sales by Type (2018-2023) & (K Units)
- Table 40. Americas AAV Vector Gene Therapy Sales by Application (2018-2023) & (K Units)
- Table 41. APAC AAV Vector Gene Therapy Sales by Region (2018-2023) & (K Units)
- Table 42. APAC AAV Vector Gene Therapy Sales Market Share by Region (2018-2023)
- Table 43. APAC AAV Vector Gene Therapy Revenue by Region (2018-2023) & (\$ Millions)
- Table 44. APAC AAV Vector Gene Therapy Revenue Market Share by Region (2018-2023)
- Table 45. APAC AAV Vector Gene Therapy Sales by Type (2018-2023) & (K Units)

Table 46. APAC AAV Vector Gene Therapy Sales by Application (2018-2023) & (K Units)

Table 47. Europe AAV Vector Gene Therapy Sales by Country (2018-2023) & (K Units)

Table 48. Europe AAV Vector Gene Therapy Sales Market Share by Country (2018-2023)

Table 49. Europe AAV Vector Gene Therapy Revenue by Country (2018-2023) & (\$ Millions)

Table 50. Europe AAV Vector Gene Therapy Revenue Market Share by Country (2018-2023)

Table 51. Europe AAV Vector Gene Therapy Sales by Type (2018-2023) & (K Units)

Table 52. Europe AAV Vector Gene Therapy Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa AAV Vector Gene Therapy Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa AAV Vector Gene Therapy Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa AAV Vector Gene Therapy Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa AAV Vector Gene Therapy Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa AAV Vector Gene Therapy Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of AAV Vector Gene Therapy

Table 60. Key Market Challenges & Risks of AAV Vector Gene Therapy

Table 61. Key Industry Trends of AAV Vector Gene Therapy

Table 62. AAV Vector Gene Therapy Raw Material

Table 63. Key Suppliers of Raw Materials

Table 64. AAV Vector Gene Therapy Distributors List

Table 65. AAV Vector Gene Therapy Customer List

Table 66. Global AAV Vector Gene Therapy Sales Forecast by Region (2024-2029) & (K Units)

Table 67. Global AAV Vector Gene Therapy Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 68. Americas AAV Vector Gene Therapy Sales Forecast by Country (2024-2029) & (K Units)

Table 69. Americas AAV Vector Gene Therapy Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 70. APAC AAV Vector Gene Therapy Sales Forecast by Region (2024-2029) & (K Units)

Table 71. APAC AAV Vector Gene Therapy Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 72. Europe AAV Vector Gene Therapy Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Europe AAV Vector Gene Therapy Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Middle East & Africa AAV Vector Gene Therapy Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Middle East & Africa AAV Vector Gene Therapy Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Global AAV Vector Gene Therapy Sales Forecast by Type (2024-2029) & (K Units)

Table 77. Global AAV Vector Gene Therapy Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 78. Global AAV Vector Gene Therapy Sales Forecast by Application (2024-2029) & (K Units)

Table 79. Global AAV Vector Gene Therapy Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 80. uniQure Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 81. uniQure AAV Vector Gene Therapy Product Portfolios and Specifications

Table 82. uniQure AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 83. uniQure Main Business

Table 84. uniQure Latest Developments

Table 85. Roche Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 86. Roche AAV Vector Gene Therapy Product Portfolios and Specifications

Table 87. Roche AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Roche Main Business

Table 89. Roche Latest Developments

Table 90. Novartis Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 91. Novartis AAV Vector Gene Therapy Product Portfolios and Specifications

Table 92. Novartis AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Novartis Main Business

Table 94. Novartis Latest Developments

Table 95. BioMarin Pharmaceutical Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 96. BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications

Table 97. BioMarin Pharmaceutical AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. BioMarin Pharmaceutical Main Business

Table 99. BioMarin Pharmaceutical Latest Developments

Table 100. Ferring Pharmaceuticals A/S Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 101. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications

Table 102. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. Ferring Pharmaceuticals A/S Main Business

Table 104. Ferring Pharmaceuticals A/S Latest Developments

Table 105. CSL Behring LLC Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 106. CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications

Table 107. CSL Behring LLC AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. CSL Behring LLC Main Business

Table 109. CSL Behring LLC Latest Developments

Table 110. PTC Therapeutics, Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 111. PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications

Table 112. PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 113. PTC Therapeutics, Inc. Main Business

Table 114. PTC Therapeutics, Inc. Latest Developments

Table 115. Pfizer Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors

Table 116. Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications

Table 117. Pfizer Inc. AAV Vector Gene Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 118. Pfizer Inc. Main Business

Table 119. Pfizer Inc. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of AAV Vector Gene Therapy

Figure 2. AAV Vector Gene Therapy Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global AAV Vector Gene Therapy Sales Growth Rate 2018-2029 (K Units)

Figure 7. Global AAV Vector Gene Therapy Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. AAV Vector Gene Therapy Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of AAV1

Figure 10. Product Picture of AAV2

Figure 11. Product Picture of AAV8

Figure 12. Product Picture of Other

Figure 13. Global AAV Vector Gene Therapy Sales Market Share by Type in 2022

Figure 14. Global AAV Vector Gene Therapy Revenue Market Share by Type (2018-2023)

Figure 15. AAV Vector Gene Therapy Consumed in Duchenne Dystrophy

Figure 16. Global AAV Vector Gene Therapy Market: Duchenne Dystrophy (2018-2023) & (K Units)

Figure 17. AAV Vector Gene Therapy Consumed in Hemophilia

Figure 18. Global AAV Vector Gene Therapy Market: Hemophilia (2018-2023) & (K Units)

Figure 19. AAV Vector Gene Therapy Consumed in Retinal Diseases

Figure 20. Global AAV Vector Gene Therapy Market: Retinal Diseases (2018-2023) & (K Units)

Figure 21. AAV Vector Gene Therapy Consumed in Other

Figure 22. Global AAV Vector Gene Therapy Market: Other (2018-2023) & (K Units)

Figure 23. Global AAV Vector Gene Therapy Sales Market Share by Application (2022)

Figure 24. Global AAV Vector Gene Therapy Revenue Market Share by Application in 2022

Figure 25. AAV Vector Gene Therapy Sales Market by Company in 2022 (K Units)

Figure 26. Global AAV Vector Gene Therapy Sales Market Share by Company in 2022

Figure 27. AAV Vector Gene Therapy Revenue Market by Company in 2022 (\$ Million)

Figure 28. Global AAV Vector Gene Therapy Revenue Market Share by Company in

2022

Figure 29. Global AAV Vector Gene Therapy Sales Market Share by Geographic Region (2018-2023)

Figure 30. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region in 2022

Figure 31. Americas AAV Vector Gene Therapy Sales 2018-2023 (K Units)

Figure 32. Americas AAV Vector Gene Therapy Revenue 2018-2023 (\$ Millions)

Figure 33. APAC AAV Vector Gene Therapy Sales 2018-2023 (K Units)

Figure 34. APAC AAV Vector Gene Therapy Revenue 2018-2023 (\$ Millions)

Figure 35. Europe AAV Vector Gene Therapy Sales 2018-2023 (K Units)

Figure 36. Europe AAV Vector Gene Therapy Revenue 2018-2023 (\$ Millions)

Figure 37. Middle East & Africa AAV Vector Gene Therapy Sales 2018-2023 (K Units)

Figure 38. Middle East & Africa AAV Vector Gene Therapy Revenue 2018-2023 (\$ Millions)

Figure 39. Americas AAV Vector Gene Therapy Sales Market Share by Country in 2022

Figure 40. Americas AAV Vector Gene Therapy Revenue Market Share by Country in 2022

Figure 41. Americas AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)

Figure 42. Americas AAV Vector Gene Therapy Sales Market Share by Application (2018-2023)

Figure 43. United States AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Canada AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Mexico AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 46. Brazil AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 47. APAC AAV Vector Gene Therapy Sales Market Share by Region in 2022

Figure 48. APAC AAV Vector Gene Therapy Revenue Market Share by Regions in 2022

Figure 49. APAC AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)

Figure 50. APAC AAV Vector Gene Therapy Sales Market Share by Application (2018-2023)

Figure 51. China AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Japan AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 53. South Korea AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Southeast Asia AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 55. India AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Australia AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 57. China Taiwan AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 58. Europe AAV Vector Gene Therapy Sales Market Share by Country in 2022

Figure 59. Europe AAV Vector Gene Therapy Revenue Market Share by Country in 2022

Figure 60. Europe AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)

Figure 61. Europe AAV Vector Gene Therapy Sales Market Share by Application (2018-2023)

Figure 62. Germany AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 63. France AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 64. UK AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Italy AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Russia AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 67. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Country in 2022

Figure 68. Middle East & Africa AAV Vector Gene Therapy Revenue Market Share by Country in 2022

Figure 69. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Type (2018-2023)

Figure 70. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Application (2018-2023)

Figure 71. Egypt AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 72. South Africa AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Israel AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Turkey AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 75. GCC Country AAV Vector Gene Therapy Revenue Growth 2018-2023 (\$ Millions)

Figure 76. Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy in 2022

Figure 77. Manufacturing Process Analysis of AAV Vector Gene Therapy

Figure 78. Industry Chain Structure of AAV Vector Gene Therapy

Figure 79. Channels of Distribution

Figure 80. Global AAV Vector Gene Therapy Sales Market Forecast by Region (2024-2029)

Figure 81. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Region (2024-2029)

Figure 82. Global AAV Vector Gene Therapy Sales Market Share Forecast by Type (2024-2029)

Figure 83. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Type (2024-2029)

Figure 84. Global AAV Vector Gene Therapy Sales Market Share Forecast by Application (2024-2029)

Figure 85. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global AAV Vector Gene Therapy Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GA91B73FBE3DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA91B73FBE3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970